Pegaspargase - Shire

Drug Profile

Pegaspargase - Shire

Alternative Names: Asparaginase macrogol; Oncaspar; PEG-asparaginase; PEG-L-asparaginase; PEGLA

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; Leadiant Biosciences; Medac; Shire
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 31 Oct 2017 Registered for Acute lymphoblastic leukaemia (Combination therapy) in Australia (IV,IM,Injection)
  • 13 Oct 2017 Committee for Medicinal Products for Human Use (CHMP) recommends approval of lyophilised formulation of pegaspargase for Acute lymphoblastic leukaemia (Combination therapy, In neonates, In infants, In children, In adolescents, In adults) in European Union
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top